> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Baxter Raises 2026 Sales And Profit Outlook, Though Adjusted EPS Falls 16% To $0.58
- URL: https://www.bullished.co/baxter-raises-2026-sales-and-profit-outlook-though-adjusted-eps-falls-16-to-0-58-196f7873/
- Published: 2026-10-29T11:37:43.000Z
- Updated: 2026-10-29T11:37:43.000Z
- Description: Third-quarter sales rose 5% to $2.98 billion, but a higher tax rate cut adjusted earnings per share from $0.69 a year earlier.
- Author: Matteo Parrino
- Tags: Earnings, BAX, Industry: Healthcare

[Baxter International](https://www.bullished.co/tag/bax/), which makes IV solutions, infusion systems and hospital beds, raised its full-year 2026 outlook on Thursday after [third-quarter sales](https://www.sec.gov/Archives/edgar/data/0000010456/000001045626000004/bax-20260930xex991.htm?ref=bullished.co) rose 5% to $2.98 billion, with growth in every segment. Adjusted earnings per share still fell 16% to $0.58 from $0.69 a year earlier, which the company blamed on a higher effective tax rate.

## Sales up, adjusted profit down

Sales grew 5% on both a reported and organic basis, the company said in its [8-K](https://www.sec.gov/Archives/edgar/data/0000010456/000001045626000004/bax-20261028.htm?ref=bullished.co) and earnings release. U.S. sales of about $1.6 billion rose 3% reported and 5% organic. International sales of about $1.4 billion rose 7% reported and 6% organic.

[Standard-accounting net income](https://www.businesswire.com/news/home/20261027278701/en/Baxter-Reports-Third-Quarter-2026-Results?ref=bullished.co) was $298 million, or $0.57 per diluted share. Adjusted earnings per share were $0.58, down 16%.

CEO Andrew Hider said Baxter delivered "a strong third quarter, with growth across all segments and divisions globally."

## Infusion gains, weaker injectables

Medical Products & Therapies sales rose 6% to [about $2.1 billion](https://www.businesswire.com/news/home/20261027278701/en/Baxter-Reports-Third-Quarter-2026-Results?ref=bullished.co). Infusion Systems, Drug Compounding and IV Solutions drove the gains, and Advanced Surgery demand also helped, while lower Injectables sales partly offset them.

Healthcare Systems & Technologies rose 4% to about $806 million, led by Care & Connectivity Solutions, with growth in Global Surgical Solutions and Patient Support Systems. Front Line Care also grew.

Baxter sells hospital, nursing home, dialysis and home-care customers a wide range of products through its own sales force, distributors and wholesalers.

## Higher guidance and debt paydown

The company now expects:

- Reported sales growth of 4% to 5%, up from 3% to 4%.
- Organic sales growth of 3% to 4%, up from 2% to 3%.
- Adjusted earnings per share of $2.05 to $2.15, up from $1.95 to $2.15.

Free cash flow was $448 million in the quarter and $705 million for the first nine months. Baxter also completed a $600 million cash tender offer that retired $864 million of debt, which it said speeds deleveraging while supporting its investment-grade credit objectives.

The board declared a quarterly dividend of $0.01 per share, payable January 4, 2027, to holders of record on November 27, 2026.

Baxter's next scheduled investor event is the J.P. Morgan Healthcare Conference on January 11-13, 2027.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — BAXTER INTERNATIONAL INC (BAX)](https://www.sec.gov/Archives/edgar/data/0000010456/000001045626000004/bax-20261028.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit bax-20260930xex991.htm — BAXTER INTERNATIONAL INC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000010456/000001045626000004/bax-20260930xex991.htm?ref=bullished.co) — SEC EDGAR
- [Baxter Reports Third-Quarter 2026 Results](https://www.businesswire.com/news/home/20261027278701/en/Baxter-Reports-Third-Quarter-2026-Results?ref=bullished.co) — businesswire.com

### More on Baxter International

- [FDA Says Baxter's Round Lake Plant Found Cephalosporin In Areas Meant To Be Free Of It](https://www.bullished.co/fda-says-baxters-round-lake-plant-found-cephalosporin-in-areas-meant-to-be-free-of-it-4e07e1d8/)

[All Baxter International (BAX) coverage →](https://www.bullished.co/tag/bax/)